SCHEMBL5134974

SCHEMBL5134974

O=C(CN1CCc2ccccc2C1c1ccccc1Cl)N(Cc1ccccc1F)C1Cc2ccccc2C1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.53
HDAC8 Q9BY41 5/20 0.39
OPRM1 P35372 1/20 0.38
FFAR2 O15552 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
DRD1 P21728 1/20 0.35
HDAC1 Q13547 4/20 0.35
HDAC3 O15379 3/20 0.35
NCOR2 Q9Y618 3/20 0.35
HDAC2 Q92769 3/20 0.35
ALDH1A1 P00352 2/20 0.35
MCHR1 Q99705 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135442 0.94 C5AR1 (0.53) C5AR1HDAC8OPRM1MEN1KMT2A
SCHEMBL5135133 0.93 C5AR1 (0.54) C5AR1HDAC8OPRM1MEN1KMT2A
SCHEMBL5136013 0.92 C5AR1 (0.56) C5AR1HDAC8OPRM1MEN1KMT2A
SCHEMBL6342543 0.92 C5AR1 (0.56) C5AR1HDAC8OPRM1MEN1KMT2A
SCHEMBL5136745 0.92 C5AR1 (0.54) C5AR1HDAC8OPRM1MEN1KMT2A
SCHEMBL5135508 0.92 C5AR1 (0.53) C5AR1HDAC8OPRM1MEN1KMT2A
SCHEMBL5134764 0.91 C5AR1 (0.48) C5AR1HDAC8MEN1KMT2ADRD1
SCHEMBL5135754 0.91 C5AR1 (0.51) C5AR1HDAC8OPRM1MEN1KMT2A
SCHEMBL5134943 0.91 C5AR1 (0.57) C5AR1HDAC8OPRM1MEN1KMT2A
SCHEMBL6230232 0.90 C5AR1 (0.56) C5AR1HDAC8OPRM1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed